Filing Flows › Health Care › Tvardi Therapeutics (TVRD)
Tvardi Therapeutics (TVRD) earnings and revenue breakdown
Latest: Q1 2025 · 10-Q filed May 13, 2025 · Tvardi Therapeutics (TVRD) Q1 2025 earnings results →
Q1 2025 Revenue up 20% year over year to $2.6M · 191¢ of every $1 of revenue lost · operating margin -92.9%
Tvardi Therapeutics made $2.6M in Q1 2025 (+20% Y/Y): Other revenue $1.3M, Collaborative revenue $1.2M, Clinical compound revenue $48K. Operating margin -92.9%, net loss $4.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed May 13, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $2.6M in Q1 2025, up 20% year over year and up 77% from the previous quarter. Other revenue was the largest line at 51% of revenue. Other revenue added $700K year over year (up 112%), 161% of the total change. Clinical compound revenue declined 43%.
Operating costs exceeded revenue by $2.4M, an operating margin of -92.9%. Total costs fell 84% while revenue rose 20%. The quarter ended with a net loss of $4.9M, narrower than the previous quarter's $7.7M loss. Net interest and other expense of $2.5M was the main reason.
Operating cash flow was −$4.7M. Non-cash charges added back $1.4M of share-based compensation. Working capital and other items used $1.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 2025 | 10-Q | May 13, 2025 | $2.6M | +20% | -92.9% | −$4.9M | −$4.7M |
| Q4 2024 | 10-K | Mar 11, 2025 | $1.5M | -52% | -372.7% | −$7.7M | −$4.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Tvardi Therapeutics
We are a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need. Based upon our founders ’ seminal work and deep understanding of the transcription factor STAT3, we have designed an innovative approach to directly inhibit STAT3, a highly validated, yet historically undruggable target. Leveraging this expertise, we are developing a pipeline of STAT3 inhibitors with a differentiated mechanism of action and convenient oral dosing.
In its own words, from its 10-K, filed Mar 31, 2026.
Tvardi Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +20% against the peers' median +10%. Operating margin: -92.9% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| TVRD Tvardi Therapeutics | Q1 2025 | $2.6M | +20% | -92.9% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Tvardi Therapeutics 10-Q on SEC EDGAR · CIK 1346830 · Pharmaceutical Preparations
13F: who owns TVRD and who is buying
More on TVRD
- How Tvardi Therapeutics makes money: revenue by segment
- Tvardi Therapeutics next earnings date and what analysts expect
- Tvardi Therapeutics stock forecast, price target and fair value
- Who owns Tvardi Therapeutics stock: holders, funds and Congress trades
- Tvardi Therapeutics recalls, complaints and regulation
History
Every quarter: Q1 2025 results · Q4 2024 results